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LETTERS TO THE EDITOR
Elevated transpulmonary gradient and cardiac
magnetic resonance-derived right ventricular
remodeling predict poor outcomes in sickle cell
disease
Recent controversies regarding the prevalence of pul
monary hypertension(PH) in patients with sickle cell dis
ease(SCD) have been raised.' While the prevalence of PH
differed among several SCD cohorts,2"4 the reported range
of 6-11 % is higher than the general population and those
with HN or scleroderma. 1 PH in SCD is often complicat
ed by concurrent left ventricular (LV) diastolic dysfunc
tion and anemia-related changes in hemodynamics. The
change in pressure across the pulmonary circulation as
reflected by the transpulmonary pressure gradient (TPG)
can be measured during right heart catheterization
(RHC). TPG is less clouded by anemia-related adapta-

tions than pulmonary vascular resistance(PVR), the more
conventional indicator of pulmonary vascular disease.
We have shown that elevation in the TPG is associated
with increased mortality, but did not explore the relation
ship of TPG to functional capacity in our previous analy
ses.4 While the morphologic cardiac manifestations of
sickle cell associated cardiomyopathy5·8 and rare left ven
tricular systolic dysfunction9 have been described, there
have been no reports using cardiac magnetic resonance
(CMR) imaging in conjunction with invasive hemody
namics to understand the relationship of TPG and right
ventricular (RV) remodeling in patients with SCD.
Accordingly, we performed a new hypothesis-generat
ing analysis to assess the relationship of RHC-derived
TPG and CMR-derived RV remodeling in patients with
SCD. We also investigated the significance of using a
TPG threshold and evidence of RV dysfunction to identi
fy patients with overall poor outcomes. Detailed patient
enrollment criteria of the Bethesda Sickle Cell Cohort and
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Table 1. Characteristics of study population.

Female
Age,years
HbSS
Hemoglobin (mg/dL)
AST(Units/L)
ALT(Units/L)
Total bilirubin(mg/dL)
Direct bilirubin(mg/dL)
Creatinine(mg/dL)
mPAP, mmHg
CVP, mmHg
PAWP, mmHg
Cl, I/minim'
SVI, mVm'
RVSWI,g/m2/beat
LVSWI,g/m'beat
PVC,mVmmHg
PVRI,dynes.s.cm-5/m'
SVR,dynes.s.cm-5
SV02,%
Right Ventricle
RVEF,%
RV ESVI,ml/m2
RV EDVI,ml/m'
RV Mass Index,g/m2
Left Ventricle
LVEF,%
LV ESVI,ml/m'
LV EDVI,ml/m'
LV Mass Index, g/m2

c

Right Heart Cath (n=84)
TPG < 12 mmHg
TPG <!: 12 mmHg
n=38
n=46

Right Heart Cath and CMR (n=41)
TPG < 12 mmHg
TPG <!: 12 mmHg
n=20
n=21

22(58%)
24(52%)
40 ± 13
41 ± 14
33(87%)
36(78%)
8.1 ± 1.6*
9.3 ± 1.5*
48 ± 24
47 ± 22
30 ± 20
31 ± 18
3.2 ± 2.2
2.9 ± 2.2
0.5 ± 0.4
0.4(0.3-0.7)
1.0 ± 0.9
0.7(0.5-1.0)
21(19-26)
37(30-45)*
9(5-10)
9(6-13)
14(12-17)
13(11-16)
5.6(4.1-6.4)
4.0(3.3-5.0)*
56(47-71)*
75(61-92)
20(15-25)*
14(10-18)
76(58-90)
54(44-77)*
3.1(2.2-5.2)*
6.8(6.0-9.1)
121 (95-166)
406(265-662)*
818(705-946)*
635(543-831)
74(71-76)
69(65-73)*
Reference Values (MESA)"
66 ± 10
27 ± 9
76 ± 15
NIA
Reference Values(Maceira et al.)'5
67 ± 5
26±5
78 ± 9
69 ± 8

11(55%)
44 ± 15
16(80%)
8.1 ± 1.7*
45 ± 28
25 ± 14
3.0 ± 1.8
0.4 ± 0.3
0.7(0.6-1.5)
21(19-26)
7(4-10)
13(11-17)
6.0(4.9-6.7)
83(68-99)
15(12-19)
84(66-93)
6.6(5.5-10.8)
116(95-144)
580(519-898)
74(69-76)

11(52%)
40 ± 15
17(81%)
9.6 ± 1.6*
48 ± 19
29 ± 12
2.9 ± 1.8
0.5 ± 0.2
0.95 ± 0.33
38(29-45)*
9(6-12)
13(12-16)
3.5(3.0-4.4)*
54(46-67) *
18(15-23)*
49(36-61)*
3.7(2.0-4.6)*
459(312-694)*
868(713 -1098)*
69(66-73)*

53(41-56)
42(34-54)
87(72-105)
23(16-30)

37(30-50)*
57(43-71)*
90(78 - 106)
26(22-33)

58(52-60)
57(45-73)
138(108-170)
81(57-91)

55 (50-60)
43(37-59)*
102(84-119)*
67(54-78)*

Average heart rates were comparable between the low vs.high TPG groups (71±13 bpm vs 73±14 bpm, P=O. 73). Reference values from the Multi-Ethnic Study of Atherosclerosis
(MESA) reflect an average of measurements for males and females. Two-tailed ? -values were calculated between those with low vs. high TPG using the Wilcoxon-Mann-Whitney
U test An asterisk (*) indicates statistical significance (P<O. 00 I).ALT alanine aminotransferase; AST aspartate aminotransferase; Cl: cardiac index; CVP: central venous pres
sure; EDVl' end-diastolic volume index; EF ejection fraction; ESVJ: end-systolic volume index; Hb: hemoglobin; LV left ventricular; LVSWJ: left ventricular stroke work index;
mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVC: pulmonary vascular capacitance (ratio of SV/PP); PVRJ: pulmonary vascular resist
ance index; RV right ventricular; RVSWJ: right ventricular stroke work index; SVJ: stroke volume index; SV02: mixed venous oxygen saturation; SVR: systemic vascular resist
ance; TPC: transpulmonary pressure gradient.
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study procedures have been described. Descriptions of
procedures and image acquisition are available in the
Online Supplementary Methods. Data from 84 consecutive
patients with RHC were analyzed; 4 1 patients under
went CMR within two days of RHC. Patient characteris
tics are summarized in Table 1. The hemodynamic com
position of sickle cell patients with normal vs. elevated
TPG are further described in the Online Supplementary
Appendix Table S 1.
Univariate analyses showed TPG ;,, 12mmHg and right
ventricular ejection fraction (RVEF) <32% were signifi
cant predictors of poor survival (Figure 1). In multivariate
analysis controlling for age and phenotype, TPG ;,,12
mmHg and RVEF <32% remained independently predic
tive of increased mortality (adjusted hazard ratio [HR]
5.47, 95% CI 1.13-26.42, P=0.035 and adjusted HR 5.11,
A TPG
95% CI 1.13-23.13, P=0.034, respectively).

;,,12mmHg identified sickle cell patients with a lower
than expected cardiac index (P<0.05) (Table 1) and hemo
dynamics consistent with ventricular interdependence.
Patients with TPG d2mmHg had a higher prevalence of
late gadolinium enhancement (LGE) at the right ventricu
lar insertion points (RVIP) (P= 0.03 0, Figure 2A) and
abnormal CMR markers of ventricular remodeling,
including increased ventricular mass index (P=0.016,
Figure 2B), increased septa-marginal trabeculae (SMT)
mass index (P=0.002), and decreased end-diastolic septal
to-LV free wall curvature ratio (P=0.013). LY eccentricity
index at end-systole was greater in those with high TPG
(P=0.026), indicative of elliptical distortion (Figure 2C).
A significant negative correlation was observed
between CMR-derived RVEF and TPG (Spearman
r=- 0.54, P<0.001). RV dysfunction was also associated
with higher New York Heart Association (NYHA) func-
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Figure 1. Hemodynamic and CMR predictors of mor
tality in patients with sickle cell disease. (A) Kaplan
Meier survival curve illustrates decreased survival
among sickle cell patients with CMR-derived RVEF
<32% (n= 41). (B) Using a combination of transpul
monary gradient (TPG) and pulmonary artery wedge
pressure (PAWP) (n= 84) as predictors, Kaplan-Meier
survival curves illustrate highest mortality in patients
with TPG 2'12mmHg and PAWP 2'15mmHg (52% [14
out of a total of 27 deaths]. P=0.001) versus the
three remaining groups. Using PAWP 2'15mmHg vs.
PAWP <15mmHg alone to dichotomize mortality
showed no statistical significance (59% [16 out of 27
deaths] vs. 41% [11 out of 27 deaths]. P=0.121). All
subjects were censored at 7.9 years. Median follow
up time was 4.7 years.
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Figure 2. CMR markers of right ventricular remodeling in sickle cell patients with an elevated transpulmonary gradient (TPG). Compared
to sickle cell patients with a transpulmonary gradient (TPG) <12mmHg, those with TPG 2'.12mmHg have (A) higher frequency of late gadolin
ium enhancement at the right ventricular insertion point (arrows), (B) higher ventricular mass index, (RV:LV ratio) and (C) higher eccentricity
index indicative of elliptical distortion at end-systole consistent with ventricular interdependence. RV: right ventricle; LV: left ventricle.
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tional classification III/N (P=0.038), and shorter 6minute walk distance (6-MWD) (P=0.043). Although the
sample size limited our ability to directly compare imag
ing and hemodynamic data in different combinations of
those with and without elevated TPG and PH, we did
observe that those with mPAP .e25mmHg and high TPG
also had a lower RVEF (6 out of 18 with RVEF <32%) and
higher mortality (10 out of 18 died). We noted that
patients with high TPG were limited in their exercise
capacity during the 6-MWD. Thirty-three percent of
patients in the high TPG group experienced NYHA class
III-N symptoms of dyspnea, angina, and syncope com
pared to 18% in the low TPG group.
Lastly, a trend for increased mortality was observed in
those with an LV EDVl ,;l15mL/m2 (HR 3.0, P=0.091), RV
EDVl .e84mL/m2 (HR 2.67, P=0.14), or RV mass index
.e34g/m2 (HR 2.93, P=0.108). An LV EDVl ,;l15mL/m2
was associated with increased symptom severity
(P=0.047) and decreased 6-MWD (P=0.003). Multivariate
analyses of continuous variables, controlling for age and
phenotype, showed significant association between LV
EDVl, ventricular mass index, and SMT mass index with
NYHA III/N classification and a 6-MWD ,;400 meters
(P<0.05).

In this hypothesis-generating analysis, we demonstrat
ed CMR evidence of RV remodeling in those with elevat
ed TPG. We found that a CMR-derived RVEF <32% was
associated with decreased survival and higher NYHA
classification. A TPG d2mmHg effectively categorizes
adults with SCD by symptom severity, functional capac
ity, mortality, and RV function.
Patients with SCD and elevated PA pressure often
demonstrate features of either pre- or post-capillary PH,
and sometimes both simultaneously, 10 but with a distinc
tive hemodynamic profile: typically borderline elevation
in mPAP and PVR along with a higher CO when com
pared to their idiopathic PAH counterpart. 0' Despite the
borderline elevation in mPAP and PVR, patients with
SCD have similar mortality rates to those with PAH. It
is accepted that normal resting mPAP is 8-20mmHg;
whereas a mPAP .e25mmHg by RHC is considered to be
the threshold for diagnosis of PH. A mPAP between 2124mmHg is of unclear clinical significance. However,
recent data12 suggest that in those with borderline mPAP,
an elevated TPG was associated with poor survival.
Vachiery et al. 13 recently called for a change in terminolo
gy when describing the contribution of a pre-capillary
component to post-capillary PH, arguing that mechanical
1

11

components of increased PAWP could trigger pulmonary
vasoconstriction and associated changes leading to pul
monary vascular disease, increased RV afterload, and,
potentially, RV failure. While not a primary aim in our
analysis, we found that TPG performed similarly to the
diastolic pulmonary vascular pressure gradient (DPG), a
marker of increasing interest. We observed that TPG and
DPG are highly correlated with Pearson's correlation
r=0.94, P<0.0001. In our modest cohort of SCD patients,
TPG and DPG performed very similarly in predicting
mortality (AUC of 0.73 [95% CI 0.61-0.86] for TPG vs.
0.74 [95% CI 0.61-0.87] for DPG, P=0.68) (Online
Supplementary Discussion). Herein, rather than classifying
sickle cell patients as having pre- or post-capillary PH or
no PH, we classified patients as having a high vs. low
TPG. This categorization allowed identification of sickle
cell patients with lower cardiac index (Cl) despite normal
LVEF and those with poor functional capacity. Previous
categorization by our group using mPAP .e25mmHg was
unable to identify those with lower Cl.4
To our knowledge, no previous report has presented
CMR evidence of RV remodeling in relation to pul
monary hemodynamics, functional capacity and progno
sis in SCD. Several groups have used CMR in small
patient populations with SCD and/or thalassemia to
describe RV and LV function,7·8 myocardial perfusion,
myocardial fibrosis,8 and myocardial iron content.6 Sickle
cell associated cardiomyopathy was described as
4-chamber dilation with some having myocardial fibro
sis, and rarely myocardial iron overload, but no correla
tive hemodynamics or prognostic data were reported.
We also observed a 4-chamber dilation. However, in
patients with high TPG, the indexed LV volumes and
mass were lower while the indexed RV volumes and
mass were higher with corresponding lower RVEF. Our
findings suggest that in patients with SCD and high TPG,
the left heart chamber is typically under-filled and CMR
findings correlate with RHC findings of higher RVSWI,
lower LVSWI, and lower LV cardiac index despite normal
LVEF. Along with RV systolic dysfunction, we observed a
higher prevalence of LGE at the RVlP in the high TPG
group, consistent with prior publications.7•
Our study has several limitations. Although 84 patients
underwent RHC, only 41 of our patients had both RHC
and CMR, which is relatively modest, but remains the
only published cohort of patients to have both hemody
namic and CMR studies. Due to the small sample size,
our findings should be interpreted as hypothesis-generat-
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ing rather than definitive conclusions. Further, the sam
ple size limitation may have increased type II errors and
therefore, our study was only able to detect large differ
ences. Because our subjects were grouped according to
TPG rather than by non-PH vs. PH based on conventional
definitions of PH, our preliminary findings should be
interpreted in the context of those having elevated TPG
vs. normal TPG rather than those with PH vs. without
PH. Additionally, our grouping based on TPG also intro
duced a degree of hemodynamic heterogeneity into our
study population when one views the population from
the conventional definition of PH vs. no PH. Despite the
limitations outlined, we were able to demonstrate statis
tical difference in many novel CMR markers indicative of
RV remodeling.
We noted higher hemoglobin in the high TPG group,
but the reasons for this may be complex. The higher
untransfused hematocrit in SCD can contribute to higher
whole blood viscosity, which may in turn contribute to
the pressure gradient across the pulmonary circulation.
PH in the sickle cell population has been associated with
higher hemolytic rate and lower hemoglobin. As a result,
clinically symptomatic patients are also more prone to
having chronic red cell transfusion therapy prior to RHC
and CMR, potentially elevating their hemoglobin and
hematocrit at the time of evaluation. These possibilities
warrant future investigation.
Our preliminary findings suggest that RV function and
morphology may have prognostic implications in
patients with SCD. While TPG may not help to pinpoint
the specific pathophysiology of PH in SCD, TPG may
reflect a composite of complex hemodynamic factors
affecting RV function, and therefore poor outcomes were
observed in SCD patients with high TPG. Rather than
using a single measurement or predictor to assess out
comes in this complex population, perhaps the role of RV
adaptation to afterload along with other hemodynamic
variables, including the TPG, merit further investigation
in a larger cohort to help guide prognosis in patients with
SCD.
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